Granzymes and perforin in solid organ transplant rejection

Cell Death and Differentiation

Volumn 17, Issue 4, 2010, Pages 567-576

  Choy, J C ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Granzyme; Perforin; Transplantation

Indexed keywords

BIOLOGICAL MARKER; CYCLOSPORIN; GRANZYME A; GRANZYME B; IMMUNOSUPPRESSIVE AGENT; PERFORIN; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT REJECTION; ARTERY INTIMA PROLIFERATION; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CHRONIC GRAFT REJECTION; DISEASE PREDISPOSITION; EFFECTOR CELL; ENDOTHELIUM INJURY; ENZYME ACTIVITY; GRAFT FAILURE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; KIDNEY TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; GRAFT REJECTION; GRANZYMES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; INFLAMMATION; MICE; PERFORIN; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

ANIMALIA;

EID: 77949500788     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.161     Document Type: Review

References (114)

1. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 2006; 25: 869-879
2. OPTN/SRTR Annual Report 2007, www.ustransplant.org.
3. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol 2008; 3 (Suppl 2): S101-S116.
4. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353-361.
5. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362-368.
6. Alexander SI, Smith N, Hu M, Verran D, Shun A, Dorney S et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 2008; 358: 369-374.
7. Parish IA, Kaech SM. Diversity in CD8(+) T cell differentiation. Curr Opin Immunol 2009; 21: 291-297.
8. Joncker NT, Raulet DH. Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev 2008; 224: 85-97.
9. Raja SM, Metkar SS, Froelich CJ. Cytotoxic granule-mediated apoptosis: unraveling the complex mechanism. Curr Opin Immunol 2003; 15: 528-532.
10. Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 2006; 6: 940-952.
11. Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 2000; 192: 1403-1414.
12. Barry M, Heibein JA, Pinkoski MJ, Lee SF, Moyer RW, Green DR et al. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol 2000; 20: 3781-3794.
13. Goping IS, Barry M, Liston P, Sawchuk T, Constantinescu G, Michalak KM et al. Granzyme B-induced apoptosis requires both direct caspase activation and relief of caspase inhibition. Immunity 2003; 18: 355-365.
14. Sutton VR, Wowk ME, Cancilla M, Trapani JA. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity 2003; 18: 319-329.
15. Goping IS, Sawchuk T, Rieger A, Shostak I, Bleackley RC. Cytotoxic T lymphocytes overcome Bcl-2 inhibition: target cells contribute to their own demise. Blood 2008; 111: 2142-2151.
16. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995; 377: 446-448.
17. Zhang D, Beresford PJ, Greenberg AH, Lieberman J. Granzymes A and B directly cleave lamins and disrupt the nuclear lamina during granule-mediated cytolysis. Proc Natl Acad Sci USA 2001; 98: 5746-5751.
18. Beresford PJ, Xia Z, Greenberg AH, Lieberman J. Granzyme A loading induces rapid cytolysis and a novel form of DNA damage independently of caspase activation. Immunity 1999; 10: 585-594.
19. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 2003; 112: 659-672.
20. Martinvalet D, Zhu P, Lieberman J. Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis. Immunity 2005; 22: 355-370.
21. Chowdhury D, Beresford PJ, Zhu P, Zhang D, Sung JS, Demple B et al. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol Cell 2006; 23: 133-142.
22. Martinvalet D, Dykxhoorn DM, Ferrini R, Lieberman J. Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell 2008; 133: 681-692.
23. Johnson H, Scorrano L, Korsmeyer SJ, Ley TJ. Cell death induced by granzyme C. Blood 2003; 101: 3093-3101.
24. Hou Q, Zhao T, Zhang H, Lu H, Zhang Q, Sun L et al. Granzyme H induces apoptosis of target tumor cells characterized by DNA fragmentation and Bid-dependent mitochondrial damage. Mol Immunol 2008; 45: 1044-1055.
25. Zhao T, Zhang H, Guo Y, Fan Z. Granzyme K directly processes bid to release cytochrome c and endonuclease G leading to mitochondria-dependent cell death. J Biol Chem 2007; 282: 12104-12111.
26. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31-37.
27. Walsh CM, Matloubian M, Liu CC, Ueda R, Kurahara CG, Christensen JL et al. Immune function in mice lacking the perforin gene. Proc Natl Acad Sci USA 1994; 91: 10854-10858.
28. Lowin B, Beermann F, Schmidt A, Tschopp J. A null mutation in the perforin gene impairs cytolytic T lymphocyte-and natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1994; 91: 11571-11575.
29. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004; 104: 735-743.
30. Kagi D, Hengartner H. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr Opin Immunol 1996; 8: 472-477.
31. Ebnet K, Hausmann M, Lehmann-Grube F, Mullbacher A, Kopf M, Lamers M et al. Granzyme A-deficient mice retain potent cell-mediated cytotoxicity. EMBO J 1995; 14: 4230-4239.
32. Zajac AJ, Dye JM, Quinn DG. Control of lymphocytic choriomeningitis virus infection in granzyme B deficient mice. Virology 2003; 305: 1-9.
33. Mullbacher A, Waring P, Tha Hla R, Tran T, Chin S, Stehle T et al. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci USA 1999; 96: 13950-13955.
34. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994; 76: 977-987.
35. Metkar SS, Menaa C, Pardo J, Wang B, Wallich R, Freudenberg M et al. Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity 2008; 29: 720-733.
36. Hanson CA, Bolling SF, Stoolman LM, Schlegelmilch JA, Abrams GD, Miska PT et al. Cytoimmunologic monitoring and heart transplantation. J Heart Transplant 1988; 7: 424-429.
37. Trentin L, Zambello R, Faggian G, Livi U, Thiene G, Gasparotto G et al. Phenotypic and functional characterization of cytotoxic cells derived from endomyocardial biopsies in human cardiac allografts. Cell Immunol 1992; 141: 332-341.
38. Schenk AD, Nozaki T, Rabant M, Valujskikh A, Fairchild RL. Donor-reactive CD8 memory T cells infiltrate cardiac allografts within 24-h posttransplant in naive recipients. Am J Transplant 2008; 8: 1652-1661.
39. Chan SY, DeBruyne LA, Goodman RE, Eichwald EJ, Bishop DK. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection. Transplantation 1995; 59: 1155-1161.
40. Youssef AR, Otley C, Mathieson PW, Smith RM. Role of CD4+ and CD8+ T cells in murine skin and heart allograft rejection across different antigenic desparities. Transpl Immunol 2004; 13: 297-304.
41. Maier S, Tertilt C, Chambron N, Gerauer K, Huser N, Heidecke CD et al. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/-mice. Nat Med 2001; 7: 557-562.
42. Kondo T, Morita K, Watarai Y, Auerbach MB, Taub DD, Novick AC et al. Early increased chemokine expression and production in murine allogeneic skin grafts is mediated by natural killer cells. Transplantation 2000; 69: 969-977.
43. Ljunggren HG, Karre K. In search of the missing self: MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237-244.
44. Hameed A, Truong LD, Price V, Kruhenbuhl O, Tschopp J. Immunohistochemical localization of granzyme B antigen in cytotoxic cells in human tissues. Am J Pathol 1991; 138: 1069-1075.
45. Griffiths GM, Namikawa R, Mueller C, Liu CC, Young JD, Billingham M et al. Granzyme A and perforin as markers for rejection in cardiac transplantation. Eur J Immunol 1991; 21: 687-693.
46. Clement MV, Haddad P, Soulie A, Benvenuti C, Lichtenheld MG, Podack ER et al. Perforin and granzyme B as markers for acute rejection in heart transplantation. Int Immunol 1991; 3: 1175-1181.
47. Lipman ML, Stevens AC, Strom TB. Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J Immunol 1994; 152: 5120-5127.
48. Kummer JA, Wever PC, Kamp AM, ten Berge IJ, Hack CE, Weening JJ. Expression of granzyme A and B proteins by cytotoxic lymphocytes involved in acute renal allograft rejection. Kidney Int 1995; 47: 70-77.
49. Krams SM, Villanueva JC, Quinn MB, Martinez OM. Expression of the cytotoxic T-cell mediator granzyme B during liver allograft rejection. Transpl Immunol 1995; 3: 162-166.
50. Legros-Maida S, Soulie A, Benvenuti C, Wargnier A, Vallee N, Berthou C et al. Granzyme B and perforin can be used as predictive markers of acute rejection in heart transplantation. Eur J Immunol 1994; 24: 229-233.
51. Rowshani AT, Florquin S, Bemelman F, Kummer JA, Hack CE, Ten Berge IJ. Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: a potential mechanism for stable renal function in patients with subclinical rejection. Kidney Int 2004; 66: 1417-1422.
52. Felzen B, Berke G, Rosen D, Coleman R, Tschopp J, Young JD et al. Effects of purified perforin and granzyme A from cytotoxic T lymphocytes on guinea pig ventricular myocytes. Cardiovasc Res 1994; 28: 643-649.
53. Alpert S, Lewis NP, Ross H, Fowler M, Valantine HA. The relationship of granzyme A and perforin expression to cardiac allograft rejection and dysfunction. Transplantation 1995; 60: 1478-1485.
54. Miltenburg AM, Meijer-Paape ME, Daha MR, van Bockel JH, Weening JJ, van Es LA et al. Donor-specific lysis of human kidney proximal tubular epithelial cells by renal allograft-infiltrating lymphocytes. Transplantation 1989; 48: 296-302.
55. Wever PC, Boonstra JG, Laterveer JC, Hack CE, van der Woude FJ, Daha MR et al. Mechanisms of lymphocyte-mediated cytotoxicity in acute renal allograft rejection. Transplantation 1998; 66: 259-264.
56. Getachew Y, Stout-Delgado H, Miller BC, Thiele DL. Granzyme C supports efficient CTL-mediated killing late in primary alloimmune responses. J Immunol 2008; 181: 7810-7817.
57. Bailey NC, Kelly CJ. Nephritogenic T cells use granzyme C as a cytotoxic mediator. Eur J Immunol 1997; 27: 2302-2309.
58. Choy JC, Wang Y, Tellides G, Pober JS. Induction of inducible NO synthase in bystander human T cells increases allogeneic responses in the vasculature. Proc Natl Acad Sci USA 2007; 104: 1313-1318.
59. Jutte NH, Heijse P, van Batenburg MH, Vaessen LM, Mochtar B, Balk AH et al. Donor heart endothelial cells as targets for graft infiltrating lymphocytes after clinical cardiac transplantation. Transpl Immunol 1993; 1: 39-44.
60. Choy JC, Cruz RP, Kerjner A, Geisbrecht J, Sawchuk T, Fraser SA et al. Granzyme B induces endothelial cell apoptosis and contributes to the development of transplant vascular disease. Am J Transplant 2005; 5: 494-499.
61. Buzza MS, Zamurs L, Sun J, Bird CH, Smith AI, Trapani JA et al. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem 2005; 280: 23549-23558.
62. Zheng L, Ben LH, Pober JS, Bothwell AL. Porcine endothelial cells, unlike human endothelial cells, can be killed by human CTL via Fas ligand and cannot be protected by Bcl-2. J Immunol 2002; 169: 6850-6855.
63. Kreisel D, Krasinskas AM, Krupnick AS, Gelman AE, Balsara KR, Popma SH et al. Vascular endothelium does not activate CD4+ direct allorecognition in graft rejection. J Immunol 2004; 173: 3027-3034.
64. Imanishi T, McBride J, Ho Q, OBrien KD, Schwartz SM, Han DK. Expression of cellular FLICE-inhibitory protein in human coronary arteries and in a rat vascular injury model. Am J Pathol 2000; 156: 125-137.
65. Bannerman DD, Tupper JC, Ricketts WA, Bennett CF, Winn RK, Harlan JM. A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis. J Biol Chem 2001; 276: 14924-14932.
66. Zheng L, Gibson TF, Schechner JS, Pober JS, Bothwell AL. Bcl-2 transduction protects human endothelial cell synthetic microvessel grafts from allogeneic T cells in vivo. J Immunol 2004; 173: 3020-3026.
67. Sis B, Famulski KS, Allanach KL, Zhu LF, Halloran PF. IFN-gamma prevents early perforin-granzyme-mediated destruction of kidney allografts by inducing donor class I products in the kidney. Am J Transplant 2007; 7: 2301-2310.
68. Schulz M, Schuurman HJ, Joergensen J, Steiner C, Meerloo T, Kagi D et al. Acute rejection of vascular heart allografts by perforin-deficient mice. Eur J Immunol 1995; 25: 474-480.
69. Halloran PF, Urmson J, Ramassar V, Melk A, Zhu LF, Halloran BP et al. Lesions of T-cell-mediated kidney allograft rejection in mice do not require perforin or granzymes A and B. Am J Transplant 2004; 4: 705-712.
70. Wasowska BA, Qian Z, Behrens E, Cangello D, Sanfilippo F, Baldwin 3rd WM. Inhibition of acute cardiac allograft rejection in immunoglobulin-deficient mice. Transplant Proc 1999; 31: 136.
71. Wasowska BA, Qian Z, Cangello DL, Behrens E, Van Tran K, Layton J et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 2001; 71: 727-736.
72. Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) 2009; 23: 34-46.
73. Uber WE, Self SE, Van Bakel AB, Pereira NL. Acute antibody-mediated rejection following heart transplantation. Am J Transplant 2007; 7: 2064-2074.
74. Bretscher PA, Havele C. Cyclosporin A can switch the immune response induced by antigen from a humoral to a cell-mediated mode. Eur J Immunol 1992; 22: 349-355.
75. Vessie EL, Hirsch GM, Lee TD. Aortic allograft vasculopathy is mediated by CD8(+) T cells in Cyclosporin A immunosuppressed mice. Transpl Immunol 2005; 15: 35-44.
76. Le Moine A, Goldman M. Non-classical pathways of cell-mediated allograft rejection: new challenges for tolerance induction? Am J Transplant 2003; 3: 101-106.
77. Miller C, DeWitt CW. Cellular and humoral responses to major and minor histocompatibility antigens. Transplant Proc 1973; 5: 303-305.
78. Choy JC, Kerjner A, Wong BW, McManus BM, Granville DJ. Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts. Am J Pathol 2004; 165: 127-133.
79. Fanslow WC, Sims JE, Sassenfeld H, Morrissey PJ, Gillis S, Dower SK et al. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 1990; 248: 739-742.
80. Shiraishi M, Csete M, Yasunaga C, McDiarmid SV, Vannice JL, Busuttil RW et al. The inhibitor cytokine interleukin-1 receptor antagonist synergistically augments cyclosporine immunosuppression in a rat cardiac allograft model. J Surg Res 1995; 58: 465-470.
81. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14: 387-397.
82. Mitchell RN, Libby P. Vascular remodeling in transplant vasculopathy. Circ Res 2007; 100: 967-978.
83. Salomon RN, Hughes CC, Schoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 1991; 138: 791-798.
84. Cramer DV, Wu GD, Chapman FA, Cajulis E, Wang HK, Makowka L. Lymphocytic subsets and histopathologic changes associated with the development of heart transplant arteriosclerosis. J Heart Lung Transplant 1992; 11 (3 Pt 1): 458-466.
85. Shi C, Lee WS, He Q, Zhang D, Fletcher Jr DL, Newell JB et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci USA 1996; 93: 4051-4056.
86. Tellides G, Pober JS. Interferon-gamma axis in graft arteriosclerosis. Circ Res 2007; 100: 622-632.
87. Choy JC, Podor TJ, Yanagawa B, Lai JC, Granville DJ, Walker DC et al. The regulation and consequences of immune-mediated cell death in atheromatous diseases. Cardiovasc Toxicol 2003; 3: 269-282.
88. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol 1977; 86: 675-684.
89. Dong C, Redenbach D, Wood S, Battistini B, Wilson JE, McManus BM. The pathogenesis of cardiac allograft vasculopathy. Curr Opin Cardiol 1996; 11: 183-190.
90. Dong C, Wilson JE, Winters GL, McManus BM. Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest 1996; 74: 921-931.
91. Lai JC, Tranfield EM, Walker DC, Dyck J, Kerjner A, Loo S et al. Ultrastructural evidence of early endothelial damage in coronary arteries of rat cardiac allografts. J Heart Lung Transplant 2003; 22: 993-1004.
92. Hameed A, Olsen KJ, Cheng L, Fox 3rd WM, Hruban RH, Podack ER. Immunohistochemical identification of cytotoxic lymphocytes using human perforin monoclonal antibody. Am J Pathol 1992; 140: 1025-1030.
93. Fox 3rd WM, Hameed A, Hutchins GM, Reitz BA, Baumgartner WA, Beschorner WE et al. Perforin expression localizing cytotoxic lymphocytes in the intimas of coronary arteries with transplant-related accelerated arteriosclerosis. Hum Pathol 1993; 24: 477-482.
94. Choy JC, McDonald PC, Suarez AC, Hung VH, Wilson JE, McManus BM et al. Granzyme B in atherosclerosis and transplant vascular disease: association with cell death and atherosclerotic disease severity. Mod Pathol 2003; 16: 460-470.
95. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation 1992; 86 (6 Suppl): III43-III46.
96. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006; 12: 1075-1080.
97. Skaro AI, Liwski RS, Zhou J, Vessie EL, Lee TD, Hirsch GM. CD8+ T cells mediate aortic allograft vasculopathy by direct killing and an interferon-gamma-dependent indirect pathway. Cardiovasc Res 2005; 65: 283-291.
98. Choy JC, Hung VH, Hunter AL, Cheung PK, Motyka B, Goping IS et al. Granzyme B induces smooth muscle cell apoptosis in the absence of perforin: involvement of extracellular matrix degradation. Arterioscler Thromb Vasc Biol 2004; 24: 2245-2250.
99. Mannon RB, Griffiths R, Ruiz P, Platt JL, Coffman TM. Absence of donor MHC antigen expression ameliorates chronic kidney allograft rejection. Kidney Int 2002; 62: 290-300.
100. Robertson H, Ali S, McDonnell BJ, Burt AD, Kirby JA. Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol 2004; 15: 390-397.
101. Sharma VK, Bologa RM, Li B, Xu GP, Lagman M, Hiscock W et al. Molecular executors of cell death-differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation 1996; 62: 1860-1866.
102. Nocera A, Tagliamacco A, Ferrante A, Fontana I, Rolla D, De Palma R et al. Cytotoxic molecule mRNA expression in chronically rejected human kidney allografts. Transplant Proc 2005; 37: 2476-2478.
103. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-756; discussion 756-757
104. Vasconcellos LM, Schachter AD, Zheng XX, Vasconcellos LH, Shapiro M, Harmon WE et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998; 66: 562-566.
105. Simon T, Opelz G, Wiesel M, Ott RC, Susal C. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant 2003; 3: 1121-1127.
106. Aquino-Dias EC, Joelsons G, da Silva DM, Berdichevski RH, Ribeiro AR, Veronese FJ et al. Non-invasive diagnosis of acute rejection in kidney transplants with delayed graft function. Kidney Int 2008; 73: 877-884.
107. Alakulppi NS, Kyllonen LE, Partanen J, Salmela KT, Laine JT. Diagnosis of acute renal allograft rejection by analyzing whole blood mRNA expression of lymphocyte marker molecules. Transplantation 2007; 83: 791-798.
108. Li B, Hartono C, Ding R, Sharma VK, Ramaswamy R, Qian B et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947-954.
109. Schoels M, Dengler TJ, Richter R, Meuer SC, Giese T. Detection of cardiac allograft rejection by real-time PCR analysis of circulating mononuclear cells. Clin Transplant 2004; 18: 513-517.
110. Hidalgo LG, Einecke G, Allanach K, Mengel M, Sis B, Mueller TF et al. The transcriptome of human cytotoxic T cells: measuring the burden of CTL-associated transcripts in human kidney transplants. Am J Transplant 2008; 8: 637-646.
111. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005; 174: 1783-1786.
112. Gondek DC, Devries V, Nowak EC, Lu LF, Bennett KA, Scott ZA et al. Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells. J Immunol 2008; 181: 4752-4760.
113. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27: 635-646.
114. Bugeon L, Cuturi MC, Paineau J, Anegon I, Soulillou JP. Similar levels of granzyme A and perforin mRNA expression in rejected and tolerated heart allografts in donor-specific tolerance in rats. Transplantation 1993; 56: 405-408.